Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 6391Neoplasms 5364Prostatic Neoplasms 2966Carcinoma, Non-Small-Cell Lung 2708Colorectal Neoplasms 2678Lung Neoplasms 2267Multiple Myeloma 1663Lymphoma 1600Neoplasm Metastasis 1551Leukemia, Myeloid, Acute 1539Melanoma 1486Pancreatic Neoplasms 1470Ovarian Neoplasms 1423Leukemia 1389Head and Neck Neoplasms 1284Precursor Cell Lymphoblastic Leukemia-Lymphoma 1282Lymphoma, Non-Hodgkin 1231Colonic Neoplasms 1159Carcinoma, Hepatocellular 1142Stomach Neoplasms 1127Leukemia, Lymphocytic, Chronic, B-Cell 1090Brain Neoplasms 1050Rectal Neoplasms 980Lymphoma, Follicular 979Recurrence 975Uterine Cervical Neoplasms 926Glioblastoma 920Carcinoma, Renal Cell 882Lymphoma, Large B-Cell, Diffuse 853Hodgkin Disease 777

Interventions

Sugars 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myelitis × Clear all
NCT02166346 2018-04-17

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

Johns Hopkins University

Phase 2 Completed
24 enrolled 10 charts

Myelitis, Myelitis, Transverse, Neuromyelitis Optica

Data powered by HemOnc (CC BY 4.0) Colophon âš¡